TY - JOUR
T1 - Assessment of country readiness for drug development
T2 - A qualitative study in Indonesia
AU - Siagian, Ria C.
AU - Ayuningtyas, Dumilah
AU - Soewondo, Prastuti
AU - Thabrany, Hasbullah
AU - Achadi, Anhari
AU - Bachtiar, Novilia S.
N1 - Funding Information:
“There has been very little financial support from the government. It is only for professors and is insufficient for drug development…” (Informant 1)
Funding Information:
The work was supported by the Badan POM to Ria C. Siagian scholarship. There was no additional external funding received for this study. The funder has no role in study design, data collection, and analysis, decision to publish, or the preparation of the manuscript.
Publisher Copyright:
© 2021 Policy Studies Organization
PY - 2021/12
Y1 - 2021/12
N2 - Over a 5-year period ending in 2019, 200 pharmaceutical industries in Indonesia were encouraged to transform from generic to research-based ones. This study aimed to assess the country's readiness for change, to predict the policy impact on drug development in Indonesia. Issues concerning the perceptions of pharmaceutical industries and government institutions on the pursuit of drug development readiness were explored in a qualitative explorative study, employing elements of key levers predicting drug development. Data from interviews and an open-ended survey of a number of top-level managers in pharmaceutical industries and relevant government institutions revealed that Indonesia was only partially ready to develop drugs. Drug characteristics, push and pull factors, government resources, and the national program were identified as drivers but failed to deliver any impact. Regulations, pharma capacity, market opportunities, regulatory-pull factors, key actors, and policy value were among the commonly stated barriers to development.
AB - Over a 5-year period ending in 2019, 200 pharmaceutical industries in Indonesia were encouraged to transform from generic to research-based ones. This study aimed to assess the country's readiness for change, to predict the policy impact on drug development in Indonesia. Issues concerning the perceptions of pharmaceutical industries and government institutions on the pursuit of drug development readiness were explored in a qualitative explorative study, employing elements of key levers predicting drug development. Data from interviews and an open-ended survey of a number of top-level managers in pharmaceutical industries and relevant government institutions revealed that Indonesia was only partially ready to develop drugs. Drug characteristics, push and pull factors, government resources, and the national program were identified as drivers but failed to deliver any impact. Regulations, pharma capacity, market opportunities, regulatory-pull factors, key actors, and policy value were among the commonly stated barriers to development.
KW - drug development
KW - government institutions
KW - pharmaceutical industry
KW - qualitative study
KW - readiness
UR - http://www.scopus.com/inward/record.url?scp=85105325245&partnerID=8YFLogxK
U2 - 10.1002/wmh3.440
DO - 10.1002/wmh3.440
M3 - Article
AN - SCOPUS:85105325245
SN - 2153-2028
VL - 13
SP - 728
EP - 748
JO - World Medical and Health Policy
JF - World Medical and Health Policy
IS - 4
ER -
